text:
Novavax, Inc. (NASDAQ:NVAX)
Q4 2013 Earnings Conference Call
March 10, 2014, 4:30 PM ET
Buck Phillips - Chief Financial Officer
Stan Erck - President and Chief Executive Officer
Louis F. Fries III - Vice President, Chief Medical Officer
Greg Glenn - Senior Vice President, Research and Development
Ted Tenthoff - Piper Jaffray
Bill Tanner - FBR Capital Markets
Kevin DeGeeter - Ladenburg
George Zavoico - H.C. Wainwright
Vernon Bernardino - MLV & Company
Good day, ladies and gentlemen, and welcome to the Novavax Fourth Quarter and Year-End Earnings Conference Call. (Operator Instructions) I'd now like to turn the call over to your host for today's conference, Mr. Buck Phillips, Chief Financial Officer. Sir, you may proceed.
Buck Phillips
Thank you. Good afternoon. This is Buck Phillips, Chief Financial Officer of Novavax. And I would like to thank everyone for joining today's call to discuss our fourth quarter 2013 financial results. Today's earnings release is currently available on our website at novavax.com and an audio archive of this conference call will be available on our website later this evening.
Joining me on today's call is Novavax's President and Chief Executive Officer, Stan Erck; and Novavax's Senior Vice President of Research and Development, Dr. Greg Glenn; as well as other members of our executive team.
Before we begin our prepared remarks, I need to remind you that we will be making forward-looking statements during this teleconference that could include financial, clinical or commercial projections. Statements relating to future financial or business performance, conditions or strategies and other financial and business related matters including expectations regarding revenue, operating expenses, cash usage and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.
I will now turn the call over to Stan Erck, President and CEO.
Stan Erck
Thanks, Buck, and good afternoon everyone. We'll be following our standard earnings call format today. I'll begin with a few remarks to review recent developments and business highlights and then I'll turn the call back over to Buck to go over the financials. We'll then open the line to take any questions you have.
So starting with 2013, Novavax made substantial progress. Our vaccine pipeline took major steps forward with multiple clinical vaccine programs demonstrating proof-of-concepts and high levels of immunogenicity. Notably, we reported data from two RSV F vaccine trials during the year, one in 330 women of childbearing age and the other in 220 elderly adults. To remind everyone, both of these trials demonstrated the safety of our vaccine candidates and both resulted in post-vaccination antibody levels which are several fold the level of antibody that would be predicted to be protective. The results represent a breakthrough and encourage us to move ahead with the RSV vaccine programs for the maternal immunization, pediatric and elderly indications in 2014.
During 2013, we were also able to demonstrate our pipeline's capabilities with regards to pandemic preparedness. In April, less than 10 days after Chinese health authorities announced an outbreak of H7N9, we were able to commence production of the recombinant vaccine and shortly thereafter initiate a clinical development program for it, the first in the world to do so. By July, the first doses of our H7N9 vaccine were injected in humans. Our vaccine proved capable producing levels of antibodies that predict production following vaccination. And we were proud to see these results available online in November and published in the December 26, 2013, edition of the New England Journal of Medicine. This is the first and to date the only published data showing the ability to produce protective antibody levels against H7N9 in a high percentage of the population.
On the strategic front, Novavax further expanded its platform during 2013 with the completed acquisition of Isconova, now referred to as Novavax AB. This acquisition brought in a novel saponin-based vaccine adjuvant technology, Matrix-M, which has been a natural and highly complementary fit for our recombinant vaccine platform. While Novavax has initiated its H7N9 clinical trial using Matrix-M, I should remind everyone that the US-based biotech company, Genocea, reported a successful use of Matrix-M with their HSV-2 vaccine candidate in Phase 1/2 trial under US IND in 2013.
Also in 2013, our capital position has improved considerably. We ended the year with more than $130 million in cash, due in large part to the successful secondary offering of $100 million that took place this past fall. Now looking ahead to 2014, we believe this year holds the potential for even greater strides forward as a leader in recombinant vaccine development. We've already made some important progress during these first few months.
Last month, we were happy to announce that our influenza contract with HHS BARDA along with its access to $97 million in funding was extended beyond the original termination date of February 2014. And also this morning, we're announcing the initiation of a Phase 1/2 clinical trial of our H7N9 avian influenza VLP vaccine candidate using the Matrix-M adjuvant technology. This trial will enroll 610 healthy subjects to evaluate safety and immunogenicity response to the vaccine and adjuvant. This trial will evaluate three different dose levels of the antigen and two dose levels of the Matrix-M adjuvant. We expect the topline safety data and - safety and immunogenicity data will be reported in the fourth quarter. This trial will lead to a dose confirmation trial in healthy and elderly adults followed by a Phase 3 immunogenicity trial.
We also recently further strengthened our management team with the addition of John Trizzino as Senior Vice President, Commercial Operations. John has played key management roles with MedImmune, which manufactures and markets FluMist and the RSV monoclonal antibody known as Synagis. He worked at ID Biomedical, which was acquired by GSK for its flu vaccine, and at Henry Schein, the largest vaccine distributor in US. John will play a key role in developing of our commercialization strategy with both the RSV and the influenza markets. We view this as a major addition to the team. Planning and preparing the market for a new product introduction is key to a successful launch. We have confidence in our platform and the data that we've been generating. We look forward to leveraging his work as we continue to move closer to approval with our vaccine candidates.
Some other milestones we expect to reach during the year include topline data from the ongoing Phase 2 clinical trial of our RSV vaccine candidate in women of childbearing age. This is currently planned for the second quarter of 2014. As I stated earlier, during the second half, we look forward to topline data from the recently initiated Phase 1/2 trial of our H7N9 pandemic influenza vaccine candidate. In the fourth quarter, we expect to initiate a Phase 2 trial of our RSV vaccine for the first time in pregnant women. And in addition, we expect to initiate the final Phase 2 trial of our novel quadrivalent seasonal influenza vaccine candidate.
And we have not yet set a date, but expect to launch a Phase 1 trial of our combination vaccine this year. We believe that this vaccine will be the first pentavalent vaccine which will contain both our RSV vaccine and our quadrivalent influenza vaccine. We're very excited by this program and look forward to reporting data from all of these trials throughout 2015.
And with that, I'll turn the call over to Buck to review our fourth quarter 2013 financial results.
Buck Phillips
Thanks, Stan. Before I continue, as was the case last quarter, I must note that the financials I'll be discussing here reflect consolidated results inclusive of our July 2013 acquisition of Isconova AB, now known as Novavax AB. My comments today will primarily focus on fourth quarter results. Results of the full year of 2013 are available in the press release we issued this afternoon.
For the fourth quarter of 2013, we reported a net loss of $14.1 million or $0.07 per share compared to a net loss of $8 million or $0.06 per share for the fourth quarter of 2012. For the full year of 2013, the net loss was $52 million or $0.31 per share compared to a net loss of $28.5 million or $0.22 per share for 2012.
Novavax had revenue in the fourth quarter of 2013 of $8.7 million as compared to $4.6 million for the same period in 2012. The increase in revenue is primarily due to the HHS BARDA amendment relating to H7N9 manufacturing and other activities as well as the PATH amendment to support the company's Phase 2 clinical trial in women of childbearing age.
Research and development expenses increased $16.3 million in the fourth quarter of '13 compared to $9.6 million for the same period in 2012, primarily as a result of the increased cost related to the company's RSV and H7N9 avian vaccine candidate clinical trials, along with higher employee related costs.
General and administrative expenses increased $4.1 million in the fourth quarter of 2013 compared to $2.5 million for the same period in 2012, resulting primarily from Novavax AB's expenses and higher professional fees.
As of December 31, 2013, the company had $133.1 million in cash, cash equivalents and investments compared to $50.3 million as of December 31, 2012. Finally, net cash used in operating activities for 2013 was $45.4 million compared to $18.2 million for 2012. The increase in cash usage from the prior year was primarily due to the higher research and development spending described before, including the company's RSV and pandemic H7N9 influenza clinical trials, as well as increased employee related costs as we grow the company.
This concludes my prepared remarks. Let me hand it back over to Stan.
Stan Erck
Thanks. That's all we have for prepared remarks today and we'll open it up to Q&A.
Question-and-Answer Session
(Operator Instructions) And our first question comes from the line of Ted Tenthoff with Piper Jaffray.
Ted Tenthoff - Piper Jaffray
I wanted to touch base first on the extension of the BARDA contracts and a quick related question. Obviously, activity is heating up here, but what kind of funds do you still expect to receive under that initial $97 million contract? And that was extended through September of this year, is that correct?
Stan Erck
So the way the BARDA contract works is back in, I think it was 2009 and early 2010, we submitted a proposal for a five-year research and development plan for, in this case, seasonal and avian influenza. And so they approved it and we started the contract in early 2011. And as with any research program, things change, the scope changes. We went from a trivalent to a quadrivalent. We used new adjuvant in the program. So trying to keep track of all those changes -
And so the contract is broken into two pieces, a three-year base period, which was predicted to be worth $97 million; and then a two-year option period to bring it up to a total of $186 million. So that base period was predicted to end in February of this year. And as it turns out, because of all the scope changes, the work wasn't going to be finished in the base period. The normal way you go about these government contracts is you get to the end of a base period, you resubmit for a what's called a no cost extension to the period which you think you'll use up all $97 million. So we've done that.
The answer to your question is, is we expect to use up the entire $97 million and then move into the option period for the additional $87 million.
Ted Tenthoff - Piper Jaffray
And related to that, [related to] [ph] the 2014 anticipated event, you say that the goal is to start a Phase 2 study, with a quadrivalent VLP seasonal vaccine in the fourth quarter. Now is that a push-out? Is that the combo that you're referring to there? Or is that the Phase 2 for just the quadrivalent? And is there some push-out considering that it will start in the fourth quarter or so? What will those remaining $30 million-plus or so for the BARDA contract go to if the Phase 2 quardrivalent study doesn't start till the fourth quarter?
Stan Erck
All of the activities that we're working on right now are an effort to sequence the development of this through to licensure. And if you start with licensure and go back, you got to run a Phase 3 program. And during that Phase 3 program, you're going to be making your consistency lots. And before you do your Phase 3 program, you've got to make the lots for Phase 3. And then we have to time the last Phase 2 before the flu season this year, so we can begin our Phase 3 next year. And so all of our activities are to scale up the process, so that we're confident that the process that we use for this Phase 2 we can just turn on the dime and start manufacturing Phase 3 materials. So that's what we're using the time for. And that trial should start before the flu season and beginning of the fourth quarter.
Our next question comes from the line of Bill Tanner with FBR Capital Markets.
Bill Tanner - FBR Capital Markets
Looks like a lot of balls moving down the field on the vaccine front. I just wondered if you could touch on how you view this feasibility of moving any or all of them through registration. And I guess really thinking more along the lines of two dimensions, one being the development capacity that you have at the company and if that's adequate or needs to be expanded, and then secondly as it relates to the capital that might be or access to capital, I guess, that would be required to do that.
Stan Erck
Yeah. So let me take the infrastructure and people part of it first and really answer the basic question. We have a very full plate. We've got a lot of successes. We've got arguably several different products coming down the platform towards licensure. We've got a quadrivalent seasonal flu. We've got a pandemic or avian influenza vaccine. We've got and then three different approaches to RSV and the maternal, pediatric and elderly. And it's possible that we would approach one or more of these with a combination pentavalent respiratory vaccine.
So do we have the capacity to do that? To date, we do. We've got 215 people in the company right now. I think roughly 180 or 185 of those people are new since I've been CEO in the last three years. We've been building up the capability to do all the things that are required, maybe not very sexy, but are required to take a product into licensure. And that includes analytical development, process development, regulatory, clinical and control quality assurance. And that's where all of our growth has been, and it's all focused on being able to take multiple products to licensure. Inevitably, one, when you're trying to work on that many things, timetables change in one program or the other. But right now, clinical data drives the clinical timeline.
And so you also asked about capital. The recently raised capital, the capital that we did last year was to be able to give us the runway to get through some clinical data points and show proof-of-concept in a couple of our different programs and initiate a Phase 3 trial, our first Phase 3 trial with flu. So we have capital to do that right now. And it's clear in the future we'll need to add to that stockpile of capital to be able to take the products through clinical FDA licensure.
Buck Phillips
Bill, let me just add, I think if you look at our numbers in the past, you'll see under investing activities in the statement of cash, Bill, you'll see what we're spending on CapEx on an annual basis. When we talk about our cash runway, we anticipate additional investment into our manufacturing facilities, our process development facilities and equipment. So you could assume that when we make statements about our cash runway, we are contemplating those investments at this point in time.
Bill Tanner - FBR Capital Markets
And then I had a couple maybe for Greg, I'm assuming he's here. As it relates to the H7N9 and Stan touched on what the expectation is for going forward, I guess, into a Phase 3, but it maybe just describing a Phase 3. I'm assuming that it's still going to be in healthy volunteers. And the extent that you view the program as being relatively de-risk, since I guess you're not going to really challenge anybody with the virus and then maybe how you view the competitive landscape and where you guys are relative to competition.
Stan Erck
This is Stan, I'm going to turn it over to Louis fries who is our head of flu program and also our Chief Medical Officer. Greg is here and [Technical difficulty].
Louis F. Fries III
The H7N9 program is based on immunogenicity. You don't do efficacy with potential pandemic vaccines. So what we will do going forward is after establishing the least dose necessary of both antigen and the adjuvant in young adults, we used to do a trial in elderly subjects, because it's important to public health authorities to cover the elderly population and especially where a pathogen like H7N9, which has a predilection to be most lethal in the elderly population. So we will do dose finding in young adults and in older adults and then move forward with those into a Phase 3 trial that allows us to get a safety database several thousand subjects and also show that our immune responses robustly fulfill CBER's criteria for accelerated approval and would more importantly make us eligible for emergency use authorization.
Our Phase 1 data was quite robust for H7N9, which is a notoriously difficult virus to immunize against. And I believe that we should have no difficulty in continuing to show robust immunogenicity, which is the name of the game for avian influenza.
Bill Tanner - FBR Capital Markets
And at the end of the day, I think you'd anticipate a more muted immune response in the elderly. I mean would this still be registerable for a viable vaccine if it's only for adults if the immunogenicity of the safety profile was viewed as maybe non-acceptable on the elderly?
Stan Erck
First of all, with adjuvanted vaccines, generally the safety profile is usually superior in the elderly. So I don't have any particular concerns residing there. It's not uncommon for both unadjuvanted and adjuvanted influenza vaccines to have a lesser immune response in the elderly. I would say that in our first study in which we enrolled individuals 18 to 64 years of age, we did look specifically at the stratum between 50 and 64 and their immune response was pretty good. And over age 64, we have the option of adjusting the adjuvant or the antigen dose to get a better response. We are not necessarily required to use the same formulation to address young adults and over adults. And so we would do that if necessary, so that we have a product that could provide protection in both age strata.
Bill Tanner - FBR Capital Markets
Just on the RSV, I don't know if anybody can provide any more granularity on the timing in the second quarter. But I guess more importantly really is what would be the key data points to look for. Clearly safety is one of them. But just in terms of trying to get some better insight into other potential efficacy indicators, how should people be thinking about the data when they come out?
Greg Glenn
Yeah, we expect to release that data in the second quarter this year. And it's an important trial. As you know, it's important data that will allow us to go to the FDA and get permission to enter into pregnant women. So the safety data is very important here. As you know, to date, we've had quite good safety. We expect that to continue. We also would be looking at the dosing regimen very carefully. And we've done, I think, a very good job of looking at the design trial to allow us to look at immune kinetics, so that we can dose the regimen during the pregnancy to provide peak antibody titers for them. So we plan on immunizing in the last trial of pregnancy which would span from about 28 weeks just to 40 weeks. So that when we immunize is going to be extremely important to decide, so that we can time immunization and get peak antibody titers.
And we do expect to look at the palivizumab antibodies, which again is very important. We'd like to reproduce that we had before. And the palivizumab, as you know, levels are important, we have indication what would be protective and we'd look to maximize those, so that when infants are born, they have the greatest chance of having protection and high palivizumab like antibodies. So this is a very key trial. We expect it to be our last trial in women of childbearing age before entering pregnant women.
Our next question comes from the line of Kevin DeGeeter with Ladenburg.
Kevin DeGeeter - Ladenburg
First off, I just want to offer my congratulations to John. Welcome back to the team. Good to have you back. And maybe two-part question on RSV and manufacturing process development. Can you just sort of walk us through, I guess, with some granularity on the key steps on scale-off between now and say initiation of a potential Phase 3 for RSV vaccine and just sort of your updated thoughts on a reasonable range for commercial COGS for an RSV standalone vaccine.
Stan Erck
So essentially the same production process as for our flu program. And then the question, just like in flu, to treat RSV is another strain and all the strains have different levels of production and of course there's different doses in a vaccine. So take those two and account how do we predict scalability and the commercial profitability on that. So in flu, as you know, the flu vaccines sell from the wholesaler at somewhere in the range of $10 to $12 per dose and it's been a trivalent dose with the cost of goods sold in below $5 for the three strains.
If we treat RSV similarly, but assume that the dose is going to be higher, it'll be more like a quadrivalent dose or perhaps a six-valent dose in terms of micrograms per dose, you can get an idea of what we expect for our cost of goods sold. The production levels at the scale that we've been doing this now are higher than any of our individual flu strains. So there's great potential for a standard pharmaceutical barge-in for RSV vaccine.
Kevin DeGeeter - Ladenburg
And maybe on a separate question with regard to the pentavalent respiratory vaccine, how do we begin to think about potential regulatory endpoints and what that means for the size of potential Phase 2 and Phase 3 studies? Specifically, I'm assume an accelerated approval under immunogenicity endpoint is unlikely for pentavalent vaccine. So how do we think about relevant clinical endpoint and what that might mean for clinical trial?
Greg Glenn
I think the most relevant clinical endpoints for a multivalent respiratory vaccine are going to be efficacy. I think we may be able to, for example, independently show efficacy with the influenza vaccine and then build off of that to demonstrate a correlate of reduced risk, which is immunologic, and then do a separate efficacy trial which involves efficacies for RSV and immunogenicity for flu. Alternatively, we could do a large single trial that look the best to see for both in influenza and the RSV components.
We're going to have to look at efficacy of both components of the influenza and the RSV in the combination product. But whether it's most opportune to do that sequentially or in one trial, I don't think we've determined yet.
Kevin DeGeeter - Ladenburg
Do you anticipate the target population for pentavalent vaccine being similar to the RSV elderly population or more akin to an influenza product label, including a broader continuum of age groups?
Greg Glenn
I think that the potential target population for the combination vaccine could be any of the population that we're pursuing in the RSV spectrum. Certainly, the elderly would benefit from the vaccine that covers both influenza, which you've seen as the major pathogen in the elderly, but which also covered RSV which is a covert cause of hospitalization. We know already that pregnant women benefit markedly from influenza vaccine. And if we could add the RSV component to that, then both mothers and infants would be likely to benefit from that. And both RSV and influenza are significant causes of morbidity in children. They have different age peaks within children, but both viruses are important in children, both in terms of causing serious illness and hospitalization and also causing relatively minor ailments, but that have tremendous economic impact based on the burden that they place on parents. So I think a combination vaccine could be a player in any of the segments where we're looking at RSV vaccine.
Your next questions comes from the line of George Zavoico with H.C. Wainwright.
George Zavoico - H.C. Wainwright
I have a question regarding the H7N9 since tomorrow. The Chinese announced that they're preparing H7N9 vaccine seeds for mass production in case of human-to-human transmission occurs, which I suspect as it seems that they're getting ready for human testing eventually. Does Novavax have a footprint at all in China, because you're ahead of the Chinese in this regard? And along with that, you have the Korean efforts going as well. So perhaps they're involved with the pandemic as well. Can you sort of triangulate China, Korea and Maryland here?
Stan Erck
So we've had several tropes and tropes planned in the near future to talk with various parts of China. As you know, there're a lot of different moving parts. But we've had conversations with the Chinese, FDA, the Chinese CDC and continued to have those. And I think it's in our part of matter of educating them as to who Novavax is and showing them the data, showing them now that we've got credibility with the US government, we've got publications in the New England Journal and showing what our capabilities are. I think they would be a potential customer. We would be a potential supplier.
I can't predict how that will go. Chinese companies have been working on H7N9 with the traditional egg-based method. And so I think we're an additional player there. Right now, without an emergency, the need for emergency use vaccine, you have to manufacture vaccines in China to be able to distribute them in China. And we've also evaluated that. So we're working all the angles in China. But there is also a lot of other countries that border China that I think have the problem of not having capacity of making H7N9 vaccines, and those are equally likely customers.
With respect to Korea, our partner in Korea, LG Life Sciences have a license to both seasonal and pandemic. And of course if there were a need for H7N9 vaccination, they would come to us for the vaccine for the time being. And their expectation, their plan is to build a manufacturing facility in Korea to supply that market in the future. But we're the only source of that right now.
Greg Glenn
I would like to point out, to date, we're the only group to have published any clinical data on the H7N9 candidate. It's March. We published at the beginning of November. So I've seen various groups making claims that they have an H7N9 vaccine at various stages of development. And no doubt, someone will publish. But to date, there has been no publication of H7N9 data. We have a very good data set.
George Zavoico - H.C. Wainwright
And so you're easily about six to nine months ahead of anybody else I presume at least?
Greg Glenn
That's right.
George Zavoico - H.C. Wainwright
And then the Chinese said that there was a dramatically engineered vaccine, which I suppose (inaudible) it's not egg-based, right?
Greg Glenn
That's correct. That still could be an egg-based or artificially constructed strain.
George Zavoico - H.C. Wainwright
I'm told it's actually there never will be from a health standpoint a pandemic H7N9 pandemic that never gets to human-to-human transmission state. But right now, there really is no customer for it or is there a plan for stockpiling regardless of whether it's called a pandemic?
Stan Erck
As I say, right now, without emergency use being demanded, our plan is to take this product on to the BARDA contract through to licensure. And once we have licensure, that's when BARDA could make their plans to start file. BARDA in the past, eight or nine years, has stockpiled a couple of billion dollars worth of vaccine. On a yearly basis, it's averaged in $100 million to $200 million. And it's difficult to predict from year-to-year how much BARDA plans to stockpile. So we can't predict that.
George Zavoico - H.C. Wainwright
And the final question regarding Isconova or Novavax AB and the nature of Matrix-M. Genocea has had successful results of the trial. Are you still marketing this as a potential adjuvant to other companies and do you expect much revenue from this regard or pretty much all your resource is directed toward, you've been talking about all afternoon so far?
Stan Erck
It's part of our plan to evaluate that. But right now, we have purchased Isconova for the primary purpose of having access to an adjuvant for our vaccines and that justified the entire acquisition. I think that what we've found since we've acquired the company is if there is a store of preclinical data and some clinical data suggesting that it might have many applications and we over the next year or so will evaluate how to exploit that.
Our next question in the queue is a follow-up from the line of Bill Tanner with FBR Capital Markets.
Bill Tanner - FBR Capital Markets
Stan, just on the registration, I mean it sounds pretty clear and feasible that the company can do what is necessary for registration in the US. As you think about global registration and have to confess a bit of near fight in terms of what might be required by other regions such as Europe or the rest of the world, to what extent would you entail having a partner for that at least just to do the registration purposes? I mean as you look farther out, to what extent would you need a partner really at all except for maybe ex-US in terms of commercialization?
Stan Erck
We'll need partners for commercialization clearly. And I think ex-US is the obvious choice for looking for partners. It's possible we'd find someone to co-market within the US, but we haven't made that decision yet. Going back to registration, as part of this great group I just told you about, we have people who have registered products globally in Europe, in the US both with our Head of Regulatory, Amy Fix, and Lou Fries have been involved in registrations outside of the US. And so we have a lot of expertise in it. And so we can do that. And the question is the timing of when we run those clinical trials and collect the data and file the registration. And so that's something we'll look at over the next year. We already have the team in place that can lead that effort.
Bill Tanner - FBR Capital Markets
But at least as it relates to Europe and the ability to leverage the data set from US clinical trials might be limited or not?
Stan Erck
I don't know it's limited.
Our next question comes from the line of Vernon Bernardino with MLV & Company.
Vernon Bernardino - MLV & Company
Just wanted to follow up on one of Bill's questions. I didn't quite catch if you had actually given an update as far as the competitive landscape in RSV.
Stan Erck
I can give that to you. So the competitive landscape to which you're referring is the one that was sponsored under a grant by the Bill & Melinda Gates Foundation and PATH, which is a not-for-profit, an NGO in Seattle, to put together an RSV landscape. I think it was December of 2012, which showed basically that every company globally that is working on vaccines has some sort of RSV vaccine candidate program, all of which were in preclinical trials, with two exceptions. There was Novavax, which was in Phase 2s back in December of 2012, way ahead of the industry at that point, and MedImmune, which has had a Phase 1/2 trial with an RSV vaccine largely working in conjunction with the NIH. And so we were basically out there by ourselves.
I think the only update that I have right now is that GSK has registered on clintrials.gov that they started to trial in August of last year with the expectation that they would report results at the end of this year or something like that. So it's a trial in healthy, adult men.
Greg Glenn
It's a sub-unit trial in healthy adult men. They don't really disclose the dosage of formulation, but that's what they tried to start their trials in adult men.
Stan Erck
So I never underestimate the competition. But there are two points from that landscape. One is, is that this is such an important area that everybody is working on some approach to RSV vaccination, number one. And number two that we remain out and front of the pack and that's largely why we've chosen to not barter the program, because we think we can progress the vaccine candidates faster through our own efforts than through partnerships.
Vernon Bernardino - MLV & Company
And as a follow-up, part of my thinking is that as you had described there are different approaches to this market as far as RSV, there're some market share gain effort and so perhaps just wanted to see how (inaudible) healthy adult men, for example, for now what is the approach to shaping this market as far as the market opportunity?
Stan Erck
So we've mentioned the three different areas that we're going into. We have RSV vaccine. I think what we're looking to do and that with a novel vaccine and the only vaccine that is approved at the time of launch, I think the market we've brought on now for the first time a commercial guy to help us do all the pre-commercialization activities to prepare the market by educating the thought leaders, the KOLs, physician community, the insurance companies and payers help to design an acceptable target product profile that enjoys marketing input and then educating groups like the Advisory Committee on Immunization Practices, for instance, and the ACOG, the gynecology group, so that we can have marketing price analysis. So that's the effort that we're going into right now and take it for an RSV vaccine alone and then factor in having a pentavalent respiratory vaccine. Not only it builds not only the RSV potential demand for market, but it encroaches upon this $3 billion flu market too. So that's what we're going to be designing.
Vernon Bernardino - MLV & Company
And bottomline, going forward, do you think everyone will have to at least generate data that shows palivizumab like antibody generation?
Greg Glenn
Well, I think it's possible via maybe other approaches. Like just would point out, our approach is highly de-risked and it's unique and novel to any vaccine development program. But it's been an activity that's been identified, evaluated in randomized clinical trials and licensed with a level that's known to be protective. So that is completely unique. And I think we felt about an important way to de-risk our programs. So at this point, that's our view that the best way forward is to follow this well proven route that has I think been a very successful product as well.
And I'm not showing any further questions in the queue. I would like to turn the call back over to the speakers for any closing remarks.
Stan Erck
Good questions. Look forward to talking with you in 90 days. Thanks.
Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
By this means the bones persons killed Indians the Western plains have been recognized years afterward.
The traveller Powell, massacred in Abyssinia, was recognized in this way.
From the presence of artificial my custom essay teeth and the mechanical appliances for fixing them, dentists may recognize their own work beyond a doubt.
One the most common-hackneyed these cases that Professor Webster.
Later cases, in which this kind proof essay proofreading service established convincing and conclusive identification, are those of Dr. Cronin, assassinated in Paris, and the bombthrower, Norcross. Every now and then accounts appear in the daily press corpses having been recognized inspection the teeth. In Washington, only a short time since, the remains an unknown man were exhumed from the Potter's Field for judicial reasons. The unrecognized body had been found in the Potomac in an advanced stage decomposition.
Essay on service
From the signs furnished the teeth the remains were identified as those a person who had disappeared mysteriously and under circumstances that pointed his having been murdered at a Virginian gambling den, and his body online essay help chat thrown into the river. In connection with this subject tragedy instructive good essay writing websites interest.
Write my essay for me
In every important case a cast the mouth should taken, in order set at rest any question that may help with papers subsequently arise as the condition the jaw, the absence teeth, their irregularity or other dental peculiarities.
A cast the mouth of the deceased in the Hillmon case showed all the teeth be regular and perfect, while alleged that Hillmon s teeth were just the opposite. External signs furnished dentition may assist greatly in fixing i need help writing a scholarship essay both age and identity. from intra-uterine life old age that maj approximately tell the age, especially children, from the teeth alone. This sign, valuable in childhood, loses its value as the dentition progresses. Elaborate tables and dental formulte found elsewhere deal with the two periods dentition, the relative position and number the teeth, and the like. At birth the jaws show points ossification only but children are sometimes born with central custom writing where to buy resume paper sign in incisors, as the writer has, in common with others, noted in several instances. The first dentition takes place from the seventh how to write dissertation the thirtieth month the second between four and five years. In rachitic children these periods are later coursework marking but a syphilitic custom resume writing taint may hasten their development. The twenty-eight teeth characterize early youth. Wisdom teeth appear between eighteen and twenty-five, sometimes as late as thirty years. The presence thirty-two teeth indicates maturity. This number sometimes exceeded. Dr.

subset: commoncrawl


text:
Water Heating
All Gas Water Heaters
All Electric Water Heaters
Tank-type Water Heaters
Hybrid Electric
Gas Tank-type
Electric Tank-type
Commercial Tank-type
Tankless Water Heaters
Condensing Tankless
Electric Tankless
Commercial Tankless
Point-of-use Water Heaters
Solar Water Heaters
Commercial Water Heaters
Heating & Cooling
Air Conditioners
Heat Pumps
Gas Furnaces
Air Handlers
Oil Furnaces
Cooling Coils
Thermostats & Controls
Package Units
Indoor Air Quality
Pool & Spa
Compact Heat Pump
Classic Heat Pump
Quiet Heat Pump
Specialty Heat Pump
Digital and Millivolt Heaters
Digital Low NOx Heaters
Electric Spa-Pak Heaters
Above Ground Heaters 106
Above Ground Heaters 156
Integrated Systems
EcoNet Integrated Controls
Heating & Water Heating
AC Package Rooftop
Commercial Products
All Water Heaters
Gas Water Heaters
Electric Water Heaters
Storage Tanks
Tankless Water Heaters
Heating & Cooling Products
Package Air Conditioners
Package Heat Pumps
Package Gas/Electric
Split System Condensing Units
Split System Heat Pumps
Air Handlers
Replacement Parts
Indoor Air Quality
Rheem History
Family of Brands
In The News
News Releases
Brand Assets
Media Contact
Energy Service Companies
K-12 Schools
Higher Education
Hospitality Industry
Business Owners
Big Box Retail
Small Box Retail
Grocery Stores
Convenience Stores
Commercial Contractors
Utility Companies
Health Care
Outpatient Centers
Assisted Living Centers
Find an Independent Contractor
Enter Postal Code (US/Canada):
Select Category:
Heating and Cooling
Tankless Water Heaters
Residential Plumbers
Solar Water Heaters
Commercial Plumbers
Solar Water Heaters
Pool and Spa Water Heaters
Home Generators
Customized Experience
Enter your US/Canadian Postal Code for a customized experience.
Enter your US/Canadian Postal Code for a customized experience.
Pool and Spa
Specialty Heat Pump Pool Heaters
Specialty Heat Pump Pool Heaters
Pool & Spa Links
Pool/Spa Heaters
Digital Gas Heater
Digital Low NOx Gas Heater
ELS 552 and 1102 Spa Heaters
Heat Pumps
Compact Heat Pump
Classic Heat Pump
Quiet Heat Pump
Specialty Heat Pump
Support Information
Warranty Information
Model not found
Search for model:
Or go to
products page
Exclusive DuraSteel™ Powder-Coated Cabinet
Polyester powder-coated, non-corrosive cabinet is more durable than plastic heat pump cabinets. Same rugged steel construction used by all the major air conditioner manufacturers.
Evaporator Coil
Large Air Coils
Raised lanced-fin design maximizes heating at lower temperatures. Rheem engineered coils are highly optimized to meet our specific design requirements. From the proper fins per inch to advanced distribution circuiting. We are the only heat pump pool heater company to actually manufacture our own coils.
Venturi Fan Cowling
High-capacity 3000-cfm fan provides unrestricted airflow for better heating. Precision engineered and manufactured cabinet design eliminates unwanted air gaps. This means more air over the coil which translates to greater efficiency.
Scroll Compressor
Scroll compressors are quiet and efficient compared to piston type compressors. They provide higher efficiency, lower sound levels, superior durability and unsurpassed reliability. The unique design of a scroll compressor actually wears in over time, not out!
Sound Isolation Pads
Prevents sound transfer to equipment pad and elevates the base pan to improve water drainage. It's the little details like this that make Rheem products stand out from the crowd.
Heat Exchanger
Spiral Titanium Tube
Our spiral titanium tube heat exchanger provides a corrosion-free waterway that can withstand the abuses of harsh pool chemistry. The spiral tube helps reduce deposit build-up and increases efficiency by performing a "scoop-and-lift" action.
Internal Bypass Valving
Automatically compensates for normal day-to-day changes in your pool's hydraulics, maximizing heat transfer efficiency.
Plumbing Connections
Off-set 2" PVC union connections are included for ease of installation.
Controls - Digital
Pool/Spa Control
Your digital heat pump pool heater can be set to have a different target temperature for your pool and spa. This allows you to dial in just the right spa temperature and never have to adjust it again. The pool can be set to a lower, more energy saving temperature.
Remote Compatible
The digital heat pump pool heater can be easily controlled by most two-wire and three-wire remote systems.
On Board Diagnostics
Tells the homeowner if there is a problem. Provides the service technician with detailed diagnostic information.
Heat-Cool Selector Switch
Go from heat mode to cool with a push of a button.
Refrigerant Circui
Reversing Valve
Heat-Cool units have a unique reversing valve that allows the heat pump pool heater to cool the pool water during the hot summer months.
Heat-Cool units have the unique ability to prevent ice from forming on the condensing coil. If freezing temperatures are sensed on the coil while heating, the unit can switch to the cooling mode. During the cooling mode, the refrigerant will be warmed by the pool water and send the hot gas to the evaporator coil to melt the ice. Once the coil temperature returns to a normal operating temperature, the unit resumes heating the water. This process only takes about 4 to 6 minutes to complete.
Power Defrost Models
Refrigerant Circuit
Hot Gas Bypass Valve
If the condensing coil senses freezing temperatures while running, the power defrost feature will activate and allow some of the hot Freon gas to bypass the water heat exchanger and reroute it back through the condensing coil. This unique feature allows the unit to continue heating the water while it removes any ice that may have formed on the coil. This feature is a great benefit when trying to operate at lower ambient temperatures.
M6350tiHC, M6350tiPD, M8350ti-E-HC
Two Sizes: 110,000 & 133,000 BUT/HR at 80/80/80
Power Defrost 117,000 BTU/HR
AHRI Certified and Listed
Scroll Compressor
Titanium spiral tube heat exchanger
2" PVC Union connections
Digital Control
COP up to 6.2 at 80/80/80, meets Florida 4.0 Minimum COP
Specialty Series Heat Pump Pool Heater
Technical Data
Warranty Information
Labor Warranty - 2 years if installed in a single family residential dwelling, 1 year if installed anywhere other than a single family residential dwelling
Parts Warranty - 7 years if installed in a single family residential dwelling, 1 year if installed anywhere other than a single family residential dwelling
Titanium tube - 10 years if installed in a single family residential dwelling, 1 year if installed anywhere other than a single family residential dwelling
quick links
Register My Product
find a contractor
Federal tax Credit
Homeowner center
Image Gallery
Company Information
About Rheem
Heart of Comfort Program
Rheem Racing Program
Privacy Policy
MAP Policy
Website Terms
Legal Information
Recall Information
Become a Contractor
Customer Support
Register Product
Contact Us
Homeowner Center
Find a Contractor
Energy Tax Credits
Energy Star Products
Savings & Energy Calculators
Earth Friendly Products
Consumer Warning
National Accounts
Builders Program
Product Categories
Heating & Cooling
Water Heating
Tankless Water Heating
Pool & Spa Heating
Solar Water Heating
Home Generators
Indoor Air Quality
Commercial Products
News Highlights
The New Rheem® Prestige® Series Hybrid Electric Water Heater: Saving Homeowners up to $4,000 in Energy Costs
Rheem Presents Industry-Leading, Energy-Efficient Home Comfort Solutions at Comfortech 2016
Rheem Announces New Sites For Its Water Heating Division
Switch to mobile
Corporate Office: 1100 Abernathy Road, Suite 1700 | Atlanta, GA 30328
© Copyright 2004-2017 Rheem Manufacturing Company | All Rights Reserved
Middle East Africa
New Zealand


text:
Women's 14k Rose Gold, Diamond, And Pink Quartz Anna Beth Earrings
$1650 From Bloomingdale's View shipping & returns info
Dana Rebecca Designs 14K Rose Gold, Diamond, and Pink Quartz Anna Beth Earrings. 14K rose gold/pink quartz. Diamonds:. 41 ct. T. W. Post back. Photo may have been enlarged and/or enhanced. All gemstone carat weights (ct. T. W. Are approximate; variance may be. 05 carat. Almost all gemstones and black diamonds have been treated to enhance their beauty and require special care. Country Of Origin: Imported.


text:
FREE SHIPPING on orders over $50.
Quantity Available:
Ellington Fans designs ceiling fans with key visual elements in mind, creating a balance between aesthetics and function in the final product.
The All-Weather Outdoor Ceiling Fan is available with the following:
- 5 ABS blades
- Remote control adaptable
- Pull chain switch
- 3 forward and reverse speeds
- Manual reverse switch on fan body
- AC motor
- Round hang-straight ceiling canopy
- Dual-mount installation: hugger or with 4" downrod
- Suspension length includes downrod
- 52" blade diameter
- 12 degree blade pitch
- Airflow: 5284 cfm (high)
- Power usage: 60.9 watts (high)
- Airflow efficiency: 86.77 cfm/watt (high)
- Suitable for outdoor use
Fan Body and Blade Finish: Aged Bronze with Weathered Oak ABS, Galvanized with Black ABS, Matte Black with Matte Black ABS, White with White ABS
Compare Brightness:
LumensThe amount of light that comes from a bulb, which has commonly been measured in watts. The more lumens, the brighter the bulb.
WattageA measurement of the power delivered to a component of an electric circuit (allowing a one-ampere current to flow through the component under the pressure of 1 volt.)
Bulb ShapeBulb shapes are denoted with a letter, which describes the shape, and a number, which indicates the size. The number indicates the diameter of the light bulb at its widest part in eighths of an inch.
BaseThe part of the bulb that connects to the fixture and its power supply. Bulb bases are denoted with the letter E, and a number which indicates the diameter of the bulb base at its widest part in millimeters.
VoltageIndicates how much voltage a bulb can accept via the fixture it's installed in.
Light Color TemperatureThe relative color from a light source, measured on the Kelvin temperature scale. Warm light is lower in color temperature (2700-3000 K) and cool, blue light is higher (5000 K).
Average Rated LifeThe average amount time that a bulb is expected to last.
CRICRI = color rendering index. This number, which can go from 0 to 100, measures the ability of a light or bulb accurately renders colors. The higher the number, the better, with most quality bulbs these days measuring at least in the 80s.
- Suspension: Length 13"
- Downrod: Length 4"
- Canopy: Diameter 5"
- Blade: Diameter 52"
Manufacturer IDs: view
Need help with some of our terminology? Check out Lumens' Lighting & Design Glossary.
Related Searches and Products
A Legacy Brass finish gives the Ellington Abbey Ceiling Fan a bit of the weight of sophistication, proudly showing its age. Subtle patterns in the Matte Opal glass shade add to the Abbey's elegance, and the reversible Walnut and Dark ...
Classic without being mundane or stuffy, the Monte Carlo Dakota Outdoor Ceiling Fan features a large drum shade of either White Opal Etched or Aged Oak glass, surrounded by thin bands of metal that continue up the fan's body to ...
Classically styled with a modern touch, the Ellington Fans Anvil Ceiling Fan offers a powerful cooling system with a tough exterior for long-lasting reliability. Featuring a 3-speed reversible motor, the Anvil Ceiling Fan carries a hammered metal fan body with ...


text:
Glowing in good ways
If you made a list of things you might want to avoid in order to live a long life, acute radiation exposure and repeated inhalation of spray paint fumes probably would be on it.
Unless, apparently, you're Ruth Stahl.
During World War II, Ruthy was in her 20s, living in Philadelphia, when she took a job painting dials on warplanes. The paint contained powder so the dials would glow in the dark for pilots doing nighttime missions.
Eventually, Ruthy also glowed in the dark.
"One night, Mother looked over at me and here I was, all aglow."
After the war, she became a gooper, the early term for crafting enthusiasts who spent their days using goopy things like glue and spray paint to make things like tin-can wreathes.
"Spray cans were like food to us," she says. "You had to have a spray can to live."
In fact, she is still spraying, most recently her patio chairs.
The kicker: Ruthy is 95. And not just any 95, but the kind of 95 you want to be.
Blond bob. Painted toenails. Cork wedges, with bling.
"I feel amazing," she says.
So what is Ruthy's secret?
Could the daily multivitamin and fish oil supplements have anything to do with it? The nap every afternoon? The good genes? (her mother and grandmother lived to 97). The chat with God every day?
If she had one guess as to what her secret is, she would lean in and tell you this:
"I'm very, very, very busy."
Up at 6 every morning, she begins with yoga and shoulder stands and is out of the house by 7 for her 3-mile power walk with younger friends (she is widowed and never had kids).
It's a walk to the Regis for coffee and a sticky bun before church on Sunday, a walk to the Ritz for coffee on Monday, lunch with the ladies on Tuesday, Bible class on Thursday and an IHOP breakfast with friends every Saturday. There's barely enough time for tending the gardens at her ocean-view Dana Point home.
Ruthy eats healthy. Dessert is half an apple, 10 almonds and three walnuts. She drinks a glass of red wine every night.
After nearly a century of living, she reports only a pain in her left foot, occasional trouble finding the right word and waning strength.
In fact she recently quit golfing her favorite course, Aliso Creek, because she could no longer hit the 90 yards needed to make it over the water.
But she just bought a new five wood and is plotting a comeback.
Ruthy drives herself to the course – in a lime green VW Bug with ribbons streaming from the antenna.
"I just had an awfully good time," she says of her life. "Well, there's so much to do in the world."
Most Popular
User Agreement
Comments are encouraged, but you must follow our Privacy Policy Policy & Terms of Use
Keep it civil and stay on topic. No profanity, vulgarity, racial slurs or personal attacks. People who harass others or joke about tragedies will be blocked. By posting your comment, you agree to allow Orange County Register Communications, Inc. the right to republish your name and comment in additional Register publications without any notification or payment.


text:
Wolfgang Puck Makes It Easy: Delicious Recipes for Your Home Kitchen - eBook
- All Products
- Academic
- Accompaniment Tracks
- Audiobooks
- Bible Accessories
- Bible Covers
- Bible Studies & Curriculum
- Bibles
- Books
- Buy in Bulk
- Catholic
- Children
- Christian Living
- Church & Pastoral
- Church Supplies
- Closeouts
- Clothing & Accessories
- Crafts & Recreation
- Download
- DVDs
- eBooks
- eBooks On Sale
- Family
- Fiction
- Gift & Home
- Homeschool
- Last Chance Bargains
- Music
- New Release
- Non-Fiction
- Pre-Order
- Slightly Imperfect
- Software
- Spanish
- Streaming Video
- Subscriptions
- Sunday School
- Teens
- Toys
Have questions about eBooks? Check out our eBook FAQs.
Product Information
|Format: DRM Protected ePub
Vendor: Thomas Nelson
Publication Date: 2007
Publisher's Description
Wolfgang Puck Makes It Easy is a groundbreaking cookbook in which Wolfgang Puck shares his creativity and genius so that anyone can prepare these wonderful recipes.
Every element of the book aims to make it incredibly easy to create great food of the highest quality and creativity, as only Wolfgang Puck can do. In addition to more than 100 recipes, the book features numerous cooking tips as well as advice on how to select the freshest ingredients, how to adapt recipes to the season, using the right cookware, and menu and wine selections.
He is creator of some of the world's greatest restaurants such as Spago and Postrio. He is known for the fast-growing Wolfgang Puck Express, a line of cooking accessories, television appearances on the Food Network, and a line of soups and pizzas. He is author of five previous cookbooks. Wolfgang Puck is one of the most visible names and faces in the food business.


text:
Check in from 15h / Check out prior to 12h
Comfort Inn & Suites Columbus (Texas): Find photos, reviews, information, amenities and compare prices for 2 stars hotels in Columbus, United States.
Boasting an outdoor pool, a Jacuzzi and a swimming pool, Comfort Inn & Suites Columbus is situated in Columbus and offers comfortable accommodation. It also provides free Wi-Fi to all guests throughout their stay.
Hotel description
The hotel's rooms are comfortable and offer a kitchenette that is equipped with a refrigerator and a microwave. They all have tea and coffee making facilities and a desk.
A satisfying breakfast is prepared each morning at Comfort Inn & Suites Columbus, and there are numerous cafés and eateries close by.
Comfort Inn provides parking and is a brief drive from Colorado County Courthouse. It is also a short car ride from Sealy and Schulenburg.
Hotel features
Room Service, Pet Friendly, Disabled Access, Air Conditioned, Non-Smoking Rooms, Refrigerator, Cable / Satellite TV, Coffee / Tea Maker, Microwave, Hair Dryer, TV, Disabled Accessible Rooms
Business Center, Concierge, Elevator / Lift, 24 Hour Reception, Conference Room(s), Multilingual Staff, Safe-Deposit Box, Wake-up Service, Meeting Rooms, Photocopier, Desk, Express Check-In/Check-Out
Fitness Room/Gym, Swimming pool, Jacuzzi, Pool Outdoor
High-speed Internet, Internet Connection (wireless)
Availability and Prices
Booking Site
Room Type
Per room
Per night
Per night
Users who viewed Comfort Inn & Suites Columbus (Texas) also viewed these 2 stars Columbus hotels:
Holiday Inn Express Hotel & Suites Columbus (Texas)
4321 Interstate 10, Columbus
4321 Interstate 10, Columbus
Americas Best Value Inn Columbus Texas
2436 Highway 71 S., Columbus
2436 Highway 71 S., Columbus
Search hotels
based on


text:
J. M. Smucker (SJM) Declares $0.75 Quarterly Dividend; 2.3% Yield
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get Alerts SJM Hot Sheet
Price: $133.57 +0.53%
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 2.3%
Revenue Growth %: -8.0%
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 2.3%
Revenue Growth %: -8.0%
Trade SJM Now!
Join SI Premium – FREE
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
J. M. Smucker (NYSE: SJM) declared a quarterly dividend of $0.75 per share, or $3 annualized.
The dividend will be payable on December 1, 2016, to stockholders of record on November 11, 2016, with an ex-dividend date of November 8, 2016.
The annual yield on the dividend is 2.3 percent.
For a dividend history and other dividend-related data on J. M. Smucker (SJM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Valero Energy Partners (VLP) Raises Quarterly Dividend 5.6% to $0.4065; 3.4% Yield
- CONE Midstream Partners (CNNX) Raises Quarterly Dividend 3.6% to $0.2724 ; 4.5% Yield
- Brink's (BCO) Declares $0.10 Quarterly Dividend; 0.9% Yield
Create E-mail Alert Related CategoriesDividends
Related EntitiesDividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!


text:
Atlantic: Great Sea Battles, Heroic Discoveries, Titanic Storms, and a Vast Ocean of a Million Storiesby Simon Winchester
"Variably genial, cautionary, lyrical, admonitory, terrifying, horrifying and inspiring…A lifetime of thought, travel, reading, imagination and memory inform this affecting account." —Kirkus Reviews (starred review)
Blending history and anecdote, geography and reminiscence, science and exposition, New York Times bestselling author Simon/b>/b>
"Variably genial, cautionary, lyrical, admonitory, terrifying, horrifying and inspiring…A lifetime of thought, travel, reading, imagination and memory inform this affecting account." —Kirkus Reviews (starred review)
Blending history and anecdote, geography and reminiscence, science and exposition, New York Times bestselling author Simon Winchester tells the breathtaking saga of the Atlantic Ocean. A gifted storyteller and consummate historian, Winchester sets the great blue sea's epic narrative against the backdrop of mankind's intellectual evolution, telling not only the story of an ocean, but the story of civilization. Fans of Winchester's Krakatoa, The Man Who Loved China, and The Professor and the Madman will love this masterful, penetrating, and resonant tale of humanity finding its way across the ocean of history.
Editorial Reviews
The Washington Post
The prolific journalist and historian returns with a story both geographically immense and profoundly personal.
Winchester (The Man Who Loved China: The Fantastic Story of the Eccentric Scientist Who Unlocked the Mysteries of the Middle Kingdom, 2008, etc.) offers a tale about the Atlantic Ocean that is variably genial, cautionary, lyrical, admonitory, terrifying, horrifying and inspiring. He begins with a memory from 1963—his youthful transatlantic crossing aboard the passenger liner Empress of Britain—and returns to the birth of the Atlantic, perhaps 540 million years ago, providing a John McPhee–like history of its formation and development. Winchester then looks at humans' "infant" acquaintance with the ocean, noting that people first settled its shores about 164,000 years ago on the western coast of Africa. They soon ventured out on the ocean, then endeavored to cross it—the Irish could have done it, he says, but there's no hard evidence. The author chronicles the stories of Leif Eriksson, John Cabot and Amerigo Vespucci, and notes that the "schoolboy" phase of the Atlantic's life includes our attempts to understand it—to chart it, measure it, discover its mineral, vegetable and animal bounties and puzzle over its mysteries. For the "lover" phase of the Atlantic's history, Winchester sails across centuries of literature, art and music that in some sense celebrate the ocean. The "soldier" phase involves warfare on and around the Atlantic, from the Vikings to the Falklands. The "justice" section examines maritime laws of various sorts, from fishing to trade to communication. The concluding chapters deal with the depletion and pollution of the ocean, and the author projects a tone of both dire warning and feathered hope. Throughout, Winchester sprinkles passages of personal history, none more powerful than the epilogue about Namibia's Skeleton Coast, "a place so named because of all the skeletons, of both men and the vessels in which they had wrecked."
A lifetime of thought, travel, reading, imagination and memory inform this affecting account.
Product Details
- 9780061702624
- Publisher:
- HarperCollins Publishers
- Publication date:
- 11/01/2011
- Series:
- P.S. Series
- Pages:
- 528
- Sales rank:
- 228,719
- Product dimensions:
- 5.20(w) x 7.90(h) x 1.00(d)
Meet the Author
Simon Winchester is the acclaimed author of many books, including The Professor and the Madman, The Men Who United the States, The Map That Changed the World, The Man Who Loved China, A Crack in the Edge of the World, and Krakatoa, all of which were New York Times bestsellers and appeared on numerous best and notable lists. In 2006, Winchester was made an officer of the Order of the British Empire (OBE) by Her Majesty the Queen. He resides in western Massachusetts.
Brief Biography
- Hometown:
- New York; Massachusetts; Scotland
- Date of Birth:
- September 28, 1944
- Place of Birth:
- London, England
- Education:
- M.A., St. Catherine¿s College, Oxford, 1966
- Website:
- http://www.simonwinchester.com
Customer Reviews
Average Review:
Most Helpful Customer Reviews
See all customer reviews
This is a solid read for anyone interested in a broad history/geography of the Atlantic Ocean. Anyone fascinated by isolated islands, plate tectonics, and transportation will enjoy this book.
A lot of good information, but the presentation lacked. The author had a penchant for run-on sentences replete with commas, dashes, colons, semicolons, etc. that was very distracting. I found myself reading some sentences two or three times before getting the meaning out of them. Also, there were far too many grammatical lapses and factual inaccuracies for a finished publication. I don't know whether this is the fault of the author or the publisher, but such should not happen. Hire some proofreaders! Further distracting was the author's use of obscure English words, when simpler wording would have made the text more readable. If he was showing off his command of the English language, he overdid it. At least in my opinion.
Full disclosure - I did not finish the book, I didn't even make it very far. I got too hung up on poor scholarship presented as incontrovertible fact and lost faith that what I was reading was a history of the Atlantic as opposed to a yarn that may be interesting to fans of florid prose but wouldn't let facts get in the way of a good story. The realization (over multiple examples in the first few tens of pages) that I just couldn't trust what was in here ruined it for me.
Extremely informative and well written. I'm pretty well read, but Winchester used a ton of words i had never seen before. I used my Nook dictionary overtime.
This is probably an interesting, perhaps fascinating, book. It is probably unfair that I write that it depresses me when I'm told twice within the first several pages that humanity is doomed and will become extinct. I don't want to read it. I'd like to think humanity will figure a way out. So, sorry, I was looking for history of the Atlantic Ocean, not this author's gloom and doom.
I love Simon Winchester's books. He's one of those few authors that you read anything they write just because it's written by them. I also happen to like the way he reads his audiobooks, so if I find him in audio I have no issue having him tell me what he has to say. "Atlantic: Great Sea Battles, Heroic Discoveries, Titanic Storms, and a Vast Ocean of a Million Stories". Wouldn't you pick a book with that massive title when it is written by one of your favorite authors? I sure did! Winchester is a geologist and he tells his story about the Atlantic Ocean from every possible perspective. He narrates it since the formation of this body of water, when it became a creek between Africa and South America some 220 million years ago, passing through its current growth of six inches a year and ending with how it will cease to exist some 180 million years from now. In between you learn about exploration, commerce, discovery, maritime biology, fishing, international law, weather, warfare, geology, boating construction, air travel, personal accomplishments and basically anything that could possibly happen where this magnificent body of water can be a part of. Historically we learn so many things about this pond containing 25% of all the water in the planet. For example, I had no idea that the Atlantic Ocean was "discovered" in the XV Century. Not because nobody had ever seen it but because nobody until then had an idea of what kind of body of water it was. The structure of the book, though, is a little bit weird for my taste. The chapters are divided in parts 1-9 and it became difficult to follow it at times and there are so many topics that you may feel a little bit lost every now and then. Also, there fact there are so many topics inevitably makes some of them boring, but it assures that every reader will find something for them when they decide to take on this incredible research accomplishment. Regardless, this is as good Winchester writing, as good Winchester writing gets. If you are a fan you will read it an enjoy it. If you are not a fan, you will still come out of this as a more knowledgeable person than when you started. That alone makes it totally worthy read. You can check more at my blog, LectumErgoSum dot com.


text:
Celebrity chefs are a new genre of "stars" promoted by a plethora of publishing outlets, web sites and TV shows for "foodies." Stardom comes with new social norms. Food is entertainment and big business, of which gourmet food is more than a niche.
Gourmet describes haute cuisine. The culinary arts are individualized and unique, and preparation is aesthetically inspiring art in presentation. Companies use "gourmet" when products are perceived ever so slightly better than the rest. Gourmet burgers are served at quick service restaurants perceived to be a class above McDonald's. There is a commixture of terms "fine dining," "high-end" and "gourmet," but for investors it is a class that offers opportunities.
Home gourmet cookware, appliance companies and exotic food and spice suppliers abound thanks to globalization. Growth of disposable income adds to the traction. The middle class celebrates meals in Michelin-starred restaurants, and is able to afford kitchen envy.
Conglomerates are gobbling up gourmet companies including confections and coffees. Nestle (OTCPK:NSRGY) wants high-end chocolates complementing its luxury line of coffee by searching the globe for an acquisition. Strauss Group, Israel's second largest in food and beverages, owns Max Brenner. It is a retail brand of exceptionally fine chocolates with chocolate restaurants and retail outlets worldwide. Max Brenner describes its chocolates as all about "sensuality and indulgence." An Israel start-up company, European Coffee Society, sells bioorganic coffee beans from roasters selling to Michelin starred restaurants throughout Europe. Gourmet brands in the portfolios of conglomerates usually remain freestanding brands.
Publicly traded companies in the restaurant business are acquiring fine dining establishments. Nickey Friedman points out, "The core strength for Del Frisco (NASDQ: DFRG) is coming from its fine-dining steak restaurants…," and the same is true of others with high-end restaurants in their portfolios.
Red Robin (NASDAQ:RRGB) is a casual, family friendly hospitality chain, employing "gourmet" to aggrandize its image. Hardly on par with Wolfgang Puck's Spago, Red Robin remains an investment opportunity worth examining.
Red Robin Gourmet Burgers trades at nearly $75 per share from a high of $86. RRBG sales top $1b annually, up over 4%. Income is up nearly 14% with a market cap exceeding $1.07b. Prestigious funds T. Rowe Price, Lord Abbett and Oppenheimer hold between 2.55% and 4.68% stakes. A new half-pound Black Angus Burger sells for $12.99 and up, raising guest checks and same store sales.
Their mission is "serving an imaginative selection of high quality gourmet burgers in a family-friendly atmosphere." The attraction is "our Gourmet Burgers and Bottomless Steak Fries and to enjoy our cocktails, non-alcoholic beverages, and other concoctions created by our Masterful Mixologists."
The fine dining overseas market is catching up to mature economies. Smergers, an online investment bank for small and medium enterprises, sees potential in India. It boasts a rising middle class with increasing disposable income, an expanding working population, urbanization, and private equity interest. India has the fewest people eating out per month. Singapore, Thailand and China have the most people patronizing restaurants, with the U.S. trailing. "Even a small increase in this number (in India) provides a huge market opportunity." If you like Indian food, investigate the investment possibilities. Hedge by finding private equity and venture capital firms investing in India restaurants and food exporters.
An article about Chef's Warehouse (NASDAQ: CHEF) on Seeking Alpha a year ago caught my interest. Then the author was bullish and long on CHEF. Its market cap was $485m, and now is $474m. The company "focuses on high-end independent restaurants (and) country clubs and some catering businesses." CHEF is a small distributor up against giant Sysco (NYSE: SYY), but with a strong business model. The company distributes 23,000 products it warehouses to more than 17,000 customers. CHEF sells specialty seafood and meats, foie gras and pate, gourmet chocolates, coffees and teas, sherry vinegar glaze, plum bitters, and organic brown rice syrup, for example.
CHEF topped $29 per share in January 2014. It is now on the low side near $19. Sales of $720m grew in the last 12 months by 40%, income is up $17%, but most importantly, customers increased by 7% over the first quarter in 2013.
Finally, in the chef appliance business take a peek at Middleby Corp (NASDQ: MIDD). It added Viking Range to its extensive collection of brands. MIDD opened in 1997 at $10 a share. It sells for $250 after touching $306 per share. It is about to split 3-for-1. Motley Fool calls it a stock of the millennium. "Middleby posted a 10-year earnings-per-share-growth rate that hovers above 30%...investors should fill up their plates," and this is a stock to never sell.
Dr. Seuss loved gourmet food. His books educate children from a young age to the wonders of gourmet food, and contribute to the efflorescing industry. His devotees are producing tasties like Lorax Cake Pops, Truffula Tree Cupcakes, Cat in the Hat Smoothies served with Green Eggs and Ham. There is Tomato and Cheese Hats, Star Belly Sneech Pancakes, Who-roast beast with Who-hash, Turtle Ice Cream Pie, Gourmet Hop on Popcorn, and the ever favorite, One Fish, Two Fish, Red Fish, Blue Fish, washed down with Pink Yink Ink Drink.
Finally, caution to investors: the gourmet food industry is more than a fad. It is an industry for long-term investment, rather than quick dollar turns. Sixty percent of restaurants fail in a few short years. Angels usually privately fund restaurants more dedicated to the culinary arts. Advice from a good accounting firm with experience in this end of the business will be invaluable.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.


text:
Would you like to save as your currency permanently or for this visit only?
Stop at Jing Kong City Hotel to discover the wonders of Hong Kong. The hotel offers a high standard of service and amenities to suit the individual needs of all travelers. Take advantage of the hotel's free Wi-Fi in all rooms, 24-hour front desk, express check-in/check-out, luggage storage, Wi-Fi in public areas. Comfortable guestrooms ensure a good night's sleep with some rooms featuring facilities such as internet access - wireless (complimentary), internet access - wireless, air conditioning, television LCD/plasma screen, television. The hotel offers various recreational opportunities. Friendly staff, great facilities and close proximity to all that Hong Kong has to offer are three great reasons you should stay at Jing Kong City Hotel.


text:
Toggle navigation
Bob Garfield:
Garfield at Large
Barbara Lippert:
MediaPost Week in Review
Online Spin
Current Stories
MediaPost Home
Today's News
Today's Opinions
Agencies &
The Agency Business
MAD: MediaPost's Agency Daily
Accounts in Review
Events Calendar
Out to Launch
People on the Move
Stan Mack's Real Mad
MAD - London
Online Media, Marketing
and Advertising
OMMA Today
Daily Online Examiner
Email Marketing Daily
Email Insider
EU Email Marketing Daily
Email Insider Europe
Mobile Shop Talk
Mobile Insider
Search Marketing Daily
Search Insider
Social Media & Marketing Daily
The Social Graf
Social Insider
Online Media, Marketing
and Advertising
Real-Time Daily
Programmatic Insider
Data & Targeting Insider
Video Daily
Video Critique
Video Insider
Publishing & Publishers
Publishers Daily
The Daily Blog
Publishing Insider
Supply Side Insider
Native Insider
IoT Daily
Connected Thinking
VR/AR Insider
AI Insider
Media Buying/Planning/Research
& The Media
Audience Buying Insider
Metrics Insider
Research Brief
TV Watch
TV Everywhere
Brand and Product Marketing
Thom Forbes: Top of the News
Engage Target Market Newsletters
Industry Sector Newsletters
Marketing Tools & Strategies
Content Marketing,
Events Home
2017 Events Calendar
Upcoming Events
Agency of the Year
January 25, 2017, NYC
Creative Media Awards
January 26, 2017, New York City
OMMA Atlanta
February 22, 2017, ATL
Brand Marketers Summit - Cross-Channel
March 7 - 10, 2017, Austin
OMMA at SXSW
March 11, 2017, TX
Appy Awards
March 15, 2017, NY
TV Insider Summit
March 19 - 22, 2017, AZ
Marketing: Automotive
April 12, 2017, NYC
Marketing Automotive Awards
April 12, 2017, NYC
Data & Programmatic Insider Summit
April 23 - 26, 2017, FL
Search Insider Summit
April 26 - 29, 2017, FL
Outfront Forum
May 3, 2017, NYC
IoT Marketing Awards
May 17, 2017, NYC
Email Insider Summit
May 31 - June 3, 2017, FL
Publishing Insider Summit
June 4 - 7, 2017, FL
Email Insider Summit Europe
June 25 - 28, 2017, TBD
Search Insider Summit Europe
June 28 - July 1, 2017, EU
Digital Out of Home Awards
September 19, 2017, NYC
Recently Concluded
Online All Stars
January 19, 2017, NY
Masters of Media Selling
January 18 - 19, 2017, NYC
Marketing: Politics
January 17, 2017, DC
Search Insider Summit
December 7 - 10, 2016, UT
Email Insider Summit
December 4 - 7, 2016, UT
OMMA Denver
November 17, 2016, CO
More Events
Content Marketing Insider Summit
Cross-Channel Marketing Insider Summit
Future of Media
IoT Marketing Forum
IOT: Shopping
Marketing Sports: Soccer in America
Marketing: Health
Mobile Insider Summit
OMMA at Advertising Week
OMMA at Internet Week
OMMA Attribution
OMMA Audience Buying
OMMA Awards
OMMA Bots & Chat
OMMA Chicago
OMMA Marketing Tech
OMMA mCommerce
OMMA Miami
OMMA Programmatic
OMMA Programmatic in New York
OMMA Programmatic TV
OMMA San Francisco
OMMA Social
OMMA Video
Social Media Insider Summit
The Reckoning
Video Insider Summit
Awards Home
Agency of the Year (January 25, 2017, NYC)
Creative Media Awards (January 26, 2017, New York City)
Appy Awards (March 15, 2017, NY)
Marketing Automotive Awards (April 12, 2017, NYC)
Digital Out of Home Awards (September 19, 2017, NYC)
Online All Stars (January 19, 2017, NY)
OMMA Awards (September 26, 2016, NYC)
Become A MediaPost Member
Subscribe to your choice of industry specific newsletters, save $100 on conferences, search member directories, comment on stories and more. Free to qualified media, marketing and advertising professionals.
Join Now
Member Resources
All Member Directory
Manage My Account
Manage My Subscriptions
Additional Resources
Feedback Loop (Comments)
Job Postings
Research Briefs
Industry Events
About and Contacts
About MediaPost
Contact Editorial
Media Kit
Advanced Search
Sign in
Remember me
Forgot your password?
Register Now
Monday, December 29, 2008
Ross Fadner, December 29, 2008, 11:00 AM
Britain Introduces Movie-Like Ratings For Web Sites
The British government is looking into rating Web sites in a similar manner to the way movies are rated by the Motion Picture Association of America in the U.S. Britain's Minister For Culture Andy Burnham told
The Daily Telegraph
that the government was planning to negotiate age ratings for English language sites with the administration of President-elect Barack Obama.
"The more we seek international solutions to this stuff -- the U.K. and the U.S. working together -- the more that an international norm will set an industry norm," Burnham said. "This is an area that is really now coming into full focus."
One possibility, he said, is forcing ISPs to offer services where the only Web sites accessible are those deemed suitable for children. Burnham claimed this was different than censorship: "This is not a campaign against free speech, far from it; it is simply there is a wider public interest at stake when it involves harm to other people. We have got to get better at defining where the public interest lies and being clear about it."
Read the whole story...
Few Ecommerce Sites Benefit From Holiday Discounts
Online retail sales may have held up better than expected during the holiday shopping season, but
The Wall Street Journal
says that this year is still likely to go down as one of the worst on record for the e-commerce sector. Online spending was down 2% year over year from Nov. 1 through Dec. 24, compared with a 5.5% to 8% drop for the overall retail market, but the bigger problem was that purchases were consolidated around big retailers like Amazon, Apple and Wal-Mart, leaving smaller online retailers in the dust.
A 2% drop in sales might not sound like a lot during a recession, but the
reminds us that this is a sector that historically increases 20% annually. As John Aiken, managing director and head of equity research for Majestic Research, says, ecommerce sales were "not amazing by any stretch."
EBay, for example, saw its traffic drop by 16% between early November and mid-December, while Best Buy saw a 17% decline, according to comScore. The
says that the few sites that did benefit relied heavily on discounts, special promotions, and targeted marketing campaigns. "Consumers are hyper-price sensitive in this environment," Aiken says, adding it isn't clear whether they will keep spending as the promotions taper off into next year.
Read the whole story...
Online Advertising To Weather Recession
It matters little what sector you're in: 2008 was a lousy year for most businesses, particularly advertising. And if you believe the forecasters, 2009 isn't supposed to be much better, either. Just last week, Barclays Capital lowered its projection for advertising in the U.S. to a negative 10% next year, with every single traditional media sector receiving a major hit. By comparison, advertising fell just 1.9% in the 1991 recession, and 6.2% in 2001.
However, while Barclays and others expect the rest of advertising to get torched, online advertising is still expected to grow between 6 and 10% next year over 2008 levels. In fact, according to
, advertising may see the kind of seismic shift next year that is now bringing about unprecedented changes to the financial and automotive sectors. "The harbinger of advertising's radical transformation is the sustained growth of online," the report says, noting while the rest of the sector takes a big hit, "online is holding its own."
A new survey from PermissionTV, which queried 400 senior-level marketing decision makers, found that online would be the least affected by budget cuts among all major commercial media. Why is that? As IAB Chief Randall Rothenberg notes, in a typical recession, "above-the-line dollars [move] below the line." Pay as you go approaches are more appealing to big advertisers than "betting one what may come" (i.e. mass-market TV/radio approaches). Instead, advertisers are looking increasingly for accountability and targeting.
Read the whole story...
Video's March To The Mainstream
A few years ago, YouTube member MadV, who usually performs magic tricks wearing a mask, put up a short video showing a simple message scrawled on his hand. It read, "One World." Then he urged viewers to respond -- and respond they did, generating some 2,000 replies, making it the most responded-to video in YouTube's history. Next, MadV stitched together each of the replies, creating one "long, voiceless montage" that Wired called "quite powerful."
It was a uniquely YouTube piece of art. But what exactly was it? It wasn't a documentary, it wasn't a conversation, and it wasn't really a commentary, either. Whatever it was, Wired notes that it would have been inconceivable without the Internet and a site like YouTube.
"What's happening to video is like what happened to word processing." Video equipment and production used to be the province of a small handful of experts who could afford the equipment. Similarly, word processing equipment used to be prohibitively expensive until Apple made it drop-dead easy, sparking an explosion of micropublishers. You could also say the same thing about photo manipulation. The next phase of video's evolution to the mainstream will occur when we get even better tools for archiving and searching video.
Read the whole story...
What Social Search Should Look Like
TechCrunch's Erick Schonfeld imagines what true social search would look like if Google and Facebook joined forces.
He says that being able to search friends' thoughts, interests and activities would provide a better experience, allowing searches for restaurants, books or movies to turn up written recommendations from people you actually know, for example. Or, if planning a trip to Europe, you could easily find out which of your friends have been to the countries you're researching and could ask for advice on where to go and what to do.
Of course, this all just a dream, Schonfeld reminds us, as it would take the union of Google and Facebook to actually make those kinds of searches possible. As it stands, the search experience on Facebook is poor, while Google's social tools lack Facebook's massive user base. "Yet social search done right could become very valuable for Facebook," Schonfeld argues, adding, "It would be even more valuable for Google." He takes us through a demonstration of how such a union might work.
Read the whole story...
Online Ads Thrive In Miserable Economy
Read the whole story...
The Internet's Free Labor Economy
Read the whole story...
Subscribe to
Around the Net In Online Marketing
Today's Issue >
Previous Issues
Friday, December 27
Thursday, December 26
Tuesday, December 24
Monday, December 23
Friday, December 20
Thursday, December 19
Wednesday, December 18
Tuesday, December 17
Monday, December 16
Friday, December 13
More Issues >
About MediaPost
Contact Editorial
RSS Feeds
Privacy/Terms & Conditions
©2017 MediaPost Communications. All rights reserved.
1460 Broadway, New York, NY 10036
tel. 212-204-2000, fax 917-591-3261,


text:
Panasonic presents new Econavi air-conditioner models
New ECONAVI room air conditioners detect and reduce waste by optimising air conditioner operations according to room conditions
KUCHING: Electrical and electronics market leader, Panasonic Malaysia Sdn Bhd (Panasonic Malaysia) announced the introduction of 10 new air conditioner models under its 'Econavi' series which boast a Sunlight Detection feature.
The Sunlight Detection feature in this series could give energy savings of up to 50 per cent for Inverter models and 35 per cent for the Deluxe Non-Inverter models through the detection of changes in sunlight intensity in the room to reduce energy wasted under restrained sunlight conditions.
In addition to this, the Econavi series is also equipped with the existing intelligent and ecologically-sound feature that helps control airflow volume and room temperature by self-detecting human presence and level of activity and self-adjusts its cooling power to reduce energy wastage.
Managing director of Panasonic Malaysia, Jeff Lee commented "These new models can help consumers bring the reduction of energy consumption to a new level and further empowers individuals to save energy easily and contribute to the environment. We are confident that this eco-friendly energy saving products will significantly appeal to the consumers and this will further enhance our market leader position."
"Consistent with our aim of creating an 'Econation', driving Malaysians to be eco-citizens; realising green lifestyles through Save, Create, Store and Manage Energy which are the key components of Panasonic Energy for an Econation. This is also a step towards our goal of becoming the No.1 Green Innovation Company in the electronics industry by 2018."
Reiterating this was Harry Sasaki, marketing director of Panasonic Malaysia, "The new Econavi models have revolutionised the way we use products and save energy. With the Econavi function turned on, savings of up to 50 per cent and 35 per cent will be attained on your electricity consumption for both Inverter and Deluxe Non-Inverter models respectively and we plan to sell more than 150,000 units by 2012."
"The entire range of Panasonic's Econavi Inverter models (1.0HP to 2.5HP) and Deluxe Non-Inverter models (1.0HP and 1.5HP) have been awarded five-star product rating for their high energy efficient air-conditioners by the Malaysia Energy Commission, based on the results of energy performance tests by Sirim Bhd."
Econavi room air-conditioners
The new Econavi with Sunlight Detection detects changes in sunlight intensity in the room to reduce the waste of cooling under less sunlight conditions. To illustrate, when weather changes from sunny to cloudy or night, Econavi detects less sunlight intensity and determines less cooling power is required.
If cooling power remains the same, then energy will be wasted. Econavi detects this waste and reduces cooling power by an amount equivalent to increasing the set temperature accordingly.
The revolutionary Panasonic Econavi utilises high-precision Human Sensor and Control Programme technologies to optimise air-conditioner operation according to room conditions. These technologies help detect unnecessary waste of energy.
At the same time, the air conditioner will also self-adjust the cooling capacity while maintaining uninterrupted cooling, comfort and convenience. Users can now enjoy higher energy savings of up to 35 per cent while maintaining uninterrupted cooling, comfort and convenience.
In addition to the Econavi and Intelligent Inverter features, both the Inverter and Deluxe Non-Inverter models also come with the new air purifying system called nanoe-G which utilises nano technology fine-particles consisting of ions and radicals to purify the air in the room. It works effectively on airborne and adhesive micro-organism such as bacteria, viruses and mould; ensuring a cleaner living environment.
Intelligent 'Inverter Technology'
Panasonic's renowned, eco-friendly Intelligent Inverter Technology has been well established as a household name when it comes to air-conditioners, thanks to the reliable and highly energy-efficient operations.
In an Inverter air-conditioner, a power conversion circuit controls the compressors' rotating speed; hence, the air-conditioner's output. Once the desired room temperature has been achieved, the Intelligent Inverter Technology reduces the rotation frequency of the compressor by alternating power supply frequency.
Hence, inverter air-conditioner runs on minimal power with precise temperature control. By reducing wasteful cooling operation, Inverter Series can achieve up to 50 per cent less energy usage compared to the non-inverter units.
In addition to energy savings, the Intelligent Inverter Technology also delivers constant comfort with wide power output range and quick cooling during the start-up period.
The new Intelligent Inverter models of room air-conditioners utilise the R410A refrigerant, which unlike other refrigerants used in conventional air-conditioners, minimises harm to the ozone layer.
In conjunction with the launch of Panasonic's Econavi room air-conditioners, customers would receive a set of queen size comforter and four pieces of bed sheet with every purchase of an Econavi Inverter model air-conditioner, and a set of queen size comforter with every purchase of the Econavi Deluxe Non-Inverter model air-conditioners.
To find out more about these new air-conditioners and the latest promotions, log on to http://www.panasonic.com.my or visit the nearest Panasonic dealer today.


text:
So apparently Virgin America will have interactive Google Maps for use in flight and they have been kind enough to make a cute little video of it in action.
TvTrip – find a hotel on the map and see it on video
OK, now I know there are a lot of sites out there that map hotel and lodging information for trip planning, but I just had to do a quick post (while we're packing up our lab for the move) about TvTrip, a European travel site that not only maps hotels in several major cities in Europe, but also offers you the opportunity to watch videos of the hotels. It also has a cool slider bar for you to set your price range. It's actually a pretty cool idea and, if other sites haven't picked up on the idea, I'm sure they will be soon. All I do know is, the movers are coming to get our computers and desks to move to our new building on Monday, and I have spent half the afternoon watching videos of hotels in Berlin and Madrid. Oh well. TvTrip only seems to have 5 cities right now: London, Paris, Madrid, Brussels, and Berlin, but if you're traveling to any of those cities, you might want to check it out.
Technology Review talks Second Earth
The online version of the latest issue (July/August 2007) of Technology Review has a fairly comprehensive article by Wade Roush about Second Life, virtual globes, social mapping, and the prospects for merging geospatial technologies and virtual world to create a Second Earth. None of the topics is especially new, but Roush does a good job of providing an overview of the various technologies and players. The main focus of the article, though, is to discuss the possibility of a Second Earth or metaverse and how that might come about. Roush starts off with the most obvious possibility, combining Second Life and Google Earth, but notes that both Google Earth and Linden Labs deny they are working on it. All in all, the article offers a nice synthesis of what's going on in relation to the development of the metaverse and the convergence with geospatial technologies, and some intriguing possibilities for the next step.
Find Recycling Near You
I ran across this site today via Digg – Find your local Recycling station! I checked our area and the data is rather mediocre at best. It has the commercial sites but none of the county wide sites that are maintained. Barb works with our county recycling authority, so I've had a pretty good chance to get acquainted with the business. Hopefully their data is a little more robust in more urban areas. It's a great idea that I hope grows and grows!
LocalHarvest – Finding fresh produce near you
I am desperately trying to get through all the email that has piled up while we were on the road, and I had to do a quick post about this site that our reader Elaine alerted me to. It's called Local Harvest, and has a nice Google Maps mashup feature that lets you see where the local farmers' markets, groceries, co-ops and farmers that sell local foods and produce, including organic, are located. So, if you like to take advantage of local foods and farmers, definitely check out Local Harvest.
I will hopefully be catching up on some other cool things I want to post, some from ISDE5 and the ESRI UC, and a couple of other projects I really like.
Upcoming GIS and web book
Scott Davis is authoring an upcoming book entitled GIS for Web Developers: Adding 'Where' to Your Web Applications from the Pragmatic Bookshelf the book will be out either June or October. Davis has been writing and speaking about GIS and web development for a couple of years.
Things the book will cover include
-Find free sources of GIS data on the web
-Browse GIS data using open source desktop viewers
-Manipulate GIS data programmatically
-Store and retrieve data using geographically-enabled databases
-Explore free web toolkits like Google Maps
-Publish and consume web services using OGC interfaces
And you can even buy a 'beta' version of the book in PDF now.
A pdf is available that outlines some of the concepts that will probably be in text (links to a pdf)
JFK Terrorists May Have Used Google Earth
The Age is reporting that the terrorists plotting to blow up JFK airport in New York may have used Google Earth in their planning. As the article states, less than a month ago, the head of the NGA offered the opinion that the US government should consider censoring satellite photos. Certainly any tool can be used for both good and evil, but hopefully this latest revelation won't have a negative impact on the emergence of these open tools.
GeoSelector – our mapping tools turned against us
The success of web mapping applications does, of course, have its drawbacks. Case in point – GeoSelector. This new mapping tool from DirectMail.com lets users define a targeted audience for direct mailings based on location and demographics and boasts a database of 220 million consumers in 110 million households. GeoSelector is built on the GoogleMaps platform, and includes added layers such as school and voting districts and census tracts. You can access GeoSelector for free, and once you have your targeted location area, you then order mailing lists based on your selection criteria (you do have to pay for the lists).
Of course, the use of geodemographics for targeted marketing is nothing new, but GeoSelector certainly lowers the bar in terms of getting access to these tools.
Via Businesswire
The NanoMetro Map – mapping nanotechnology hotspots
I haven't posted about a Google Maps mashup in awhile, but this one, called Putting Nanotechnology on the Map, offers an interesting perspective on where nanotechnology research hotspots are located in the US, including universities, private companies and government facilities. Some of the centers, like the San Francisco Bay area, are no surprise, but I was kind of amazed by the number of companies and universities that are engaged in nanotechnology research and business in places I wouldn't necessarily think of, like Montana or Idaho.
One way to avoid getting sick
Ever wonder how accurate that phrase, "It's going around" really is? Well now you can figure it out with Who is Sick? This is sort of epidemiology amateur style. Anyone can post their symptoms along with where they're located. So if you're feeling a tad under the weather, give the site a shot and see if whatever you have is "going around" in your area.